Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 3/20 | 0.64 |
| ▸ | WHR1 | P49842 | 1/20 | 0.58 |
| ▸ | CCR4 | P51679 | 13/20 | 0.56 |
| ▸ | EGFR | P00533 | 2/20 | 0.51 |
| ▸ | RET | P07949 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15280598 | 0.83 | CCR4 (0.67) | EHMT2WHR1CCR4 | |
| SCHEMBL15280268 | 0.82 | HRH4 (0.70) | EHMT2WHR1CCR4 | |
| SCHEMBL15280457 | 0.81 | WHR1 (0.64) | EHMT2WHR1CCR4HTR2A | |
| SCHEMBL15280448 | 0.81 | CCR4 (0.61) | EHMT2WHR1CCR4 | |
| SCHEMBL22144612 | 0.80 | WHR1 (0.85) | EHMT2WHR1CCR4 | |
| SCHEMBL15280261 | 0.78 | EHMT2 (1.00) | EHMT2 | |
| SCHEMBL15280238 | 0.78 | EHMT2 (0.65) | EHMT2WHR1CCR4EGFRRET | |
| SCHEMBL15280409 | 0.77 | EHMT2 (0.92) | EHMT2 | |
| SCHEMBL15280406 | 0.77 | EHMT2 (0.78) | EHMT2 | |
| SCHEMBL23073423 | 0.76 | EHMT2 (0.70) | EHMT2CCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2828250-B1 | QUINAZOLINE COMPOUNDS AND THEIR USE IN THERAPY | IMPERIAL COLLEGE INNOVATIONS LTD (GB) | 2021-03-10 | — | — | EP | disclosed |
| US-9932317-B2 | Quinazoline compounds and their use in therapy | IMPERIAL INNOVATIONS LIMITED (GB) | 2018-04-03 | — | — | US | disclosed |
| US-9932317-B2 | Quinazoline compounds and their use in therapy | IMPERIAL INNOVATIONS LIMITED (GB) | 2018-04-03 | — | — | US | disclosed |
| US-20150057263-A1 | Quinazoline Compounds And Their Use In Therapy | IMPERIAL WHITE CITY INCUBATOR LIMITED (GB) | 2015-02-26 | — | — | US | disclosed |
| US-20150057263-A1 | Quinazoline Compounds And Their Use In Therapy | IMPERIAL WHITE CITY INCUBATOR LIMITED (GB) | 2015-02-26 | — | — | US | disclosed |
| WO-2013140148-A1 | QUINAZOLINE COMPOUNDS AND THEIR USE IN THERAPY | IMPERIAL INNOVATIONS LIMITED (GB) | 2013-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057263-A1 | Quinazoline Compounds And Their Use In Therapy | EZH2, EHMT1, HNMT | EHMT2 4/4885WHR1 1384/4885CCR4 4749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.